TransCode Therapeutics, Inc. has announced the publication of peer-reviewed preclinical research supporting the use of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in orthotopic glioblastoma models. This delivery significantly increased tumor cell apoptosis and resulted in a statistically significant improvement in survival.
The findings validate TransCode's TTX delivery platform and support the potential advancement of TTX-MC138 into future clinical evaluation for patients with glioblastoma. This builds on completed IND-enabling studies and existing Phase 1 clinical experience outside the central nervous system. Glioblastoma multiforme represents one of the most aggressive forms of brain cancer, with limited treatment options and poor prognosis for patients, making this research particularly significant.
TransCode Therapeutics is a clinical stage company pioneering immunoncology and RNA therapeutic treatments of high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. The full press release detailing these findings is available at https://ibn.fm/XdHxZ.
The research demonstrates that systemic delivery methods can effectively target brain tumors, which is crucial for treating cancers that have traditionally been difficult to reach with therapeutic agents. The statistically significant improvement in survival observed in preclinical models suggests potential clinical benefits for human patients facing this devastating diagnosis. These findings come at a critical time when new approaches to treating aggressive brain cancers are urgently needed.
TransCode maintains a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. This research represents an important step forward in developing targeted therapies for cancers that have proven resistant to conventional treatments, potentially offering new hope for patients with limited options.
